Denali Therapeutics (DNLI) Net Income towards Common Stockholders (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Net Income towards Common Stockholders data on file, last reported at -$129.0 million in Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders rose 5.05% year-over-year to -$129.0 million in Q1 2026; TTM through Mar 2026 was -$562.5 million, a 20.88% decrease from a year earlier, with the FY2025 full-year figure at -$512.5 million, down 21.23% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$129.0 million, up from -$131.4 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for DNLI reached as high as $183.4 million in Q2 2023 and fell as low as -$172.2 million in Q2 2025.
• Historically, Net Income towards Common Stockholders has averaged -$94.7 million across 5 years, with a median of -$110.1 million in 2024.
• Across the five-year window, Net Income towards Common Stockholders surged 411.91% in 2023 and tumbled 155.56% in 2024, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$98.7 million in 2022, then fell by 21.07% to -$119.5 million in 2023, then increased by 1.59% to -$117.6 million in 2024, then decreased by 11.79% to -$131.4 million in 2025, then rose by 1.84% to -$129.0 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$129.0 million in Q1 2026, -$131.4 million in Q4 2025, and -$129.9 million in Q3 2025.